High Cholesterol

Clinical Trial Finder

Many patients with high cholesterol are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Nattokinase Supplementation and Hemostatic Factors

Condition:   Hypercholesterolemia
Interventions:   Dietary Supplement: Nattokinase;   Dietary Supplement: Placebo
Sponsor:   Yonsei University
Completed - verified September 2016

Feasibility and Acceptability of a Beverage Intervention for Hispanic Adults

Conditions:   Obesity;   Hypercholesterolemia;   Hyperglycemia;   Hypertriglyceridemia
Interventions:   Other: Mediterranean Lemonade;   Other: Green Tea;   Other: Flavored Water
Sponsor:   University of Arizona
Recruiting - verified July 2016

Comprehensive Treatment of Angina in Women With Microvascular Dysfunction

Conditions:   Angina Pectoris;   Coronary Microvascular Disease
Interventions:   Dietary Supplement: Diet;   Behavioral: Training;   Drug: Medication (with statin and ACE-inhibition)
Sponsors:   Bispebjerg Hospital;   University Hospital Bispebjerg and Frederiksberg;   Cambridge Weight Plan Limited
Not yet recruiting - verified September 2016

Cholesterol and Statin in Healthy Adults

Condition:   Nutritional Interventions to Treat Conditions Associated With Elevated HMB Excretion
Intervention:   Other: Statin user
Sponsor:   Texas A&M University
Recruiting - verified September 2016

An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

Condition:   Hypercholesterolaemia
Interventions:   Drug: alirocumab SAR236553 (REGN727);   Drug: statins;   Drug: ezetimibe;   Drug: cholestyramine;   Drug: fenofibrate;   Drug: omega-3 fatty acids;   Drug: nicotinic acid
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified September 2016

De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised Study

Condition:   Liver Transplantation
Interventions:   Drug: Tacrolimus;   Drug: Everolimus;   Drug: Mycophenolate mofetil;   Drug: Prednisolone, Prednisone or Methylprednisolone
Sponsor:   Rennes University Hospital
Not yet recruiting - verified September 2016

Study to Evaluate the Safety of Repatha® in Pregnancy

Conditions:   Hypercholesterolaemia;   Pregnancy
Intervention:  
Sponsor:   Amgen
Not yet recruiting - verified September 2016

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension

Condition:   Dyslipidemia
Intervention:   Biological: Evolocumab
Sponsor:   Amgen
Recruiting - verified September 2016

Chart Review of Repatha® in Subjects With Hyperlipidaemia

Condition:   Hypercholesterolaemia
Intervention:  
Sponsor:   Amgen
Recruiting - verified September 2016

Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany

Conditions:   Type 1 Diabetes;   Familial Hypercholesterolemia
Intervention:  
Sponsor:   Kinderkrankenhaus auf der Bult
Not yet recruiting - verified September 2016

A Study in Subjects With Type 2 Diabetes Mellitus With Hypercholesterolemia/Mixed Dyslipidemia

Conditions:   Hypercholesterolemia;   Mixed Dyslipidemia;   Type 2 Diabetes
Interventions:   Biological: Evolocumab;   Other: Placebo to Evolocumab
Sponsor:   Amgen
Recruiting - verified September 2016

A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832)

Condition:   Hypercholesterolemia
Interventions:   Drug: Ezetimibe 10 mg;   Drug: Rosuvastatin 2.5 mg;   Drug: Placebo for Ezetimibe;   Drug: Placebo for Rosuvastatin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified September 2016

Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia

Condition:   Hypercholesterolemia
Interventions:   Drug: alirocumab SAR236553 (REGN727);   Drug: placebo for alirocumab;   Drug: ezetimibe;   Drug: placebo for ezetimibe;   Drug: atorvastatin;   Drug: rosuvastatin;   Drug: simvastatin
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified September 2016

Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

Condition:   Hypercholesterolaemia
Interventions:   Drug: ALIROCUMAB SAR236553 (REGN727);   Drug: placebo;   Drug: insulin;   Drug: insulin;   Drug: statin;   Drug: lipid modifying therapy
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Active, not recruiting - verified September 2016

Trial Assessing Evolocumab(AMG145) Compared to LDL-C Apheresis in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment

Condition:   Hypercholesterolemia
Interventions:   Biological: evolocumab (AMG 145);   Other: Low Density Lipoprotein Cholesterol (LDL-C) Apheresis
Sponsor:   Amgen
Active, not recruiting - verified September 2016

Atorvastatin Effectiveness and Safety in Cardiology Patients in Real World Setting

Condition:   Coronary Artery Disease, Hypercholesterolemia, Hypertension
Intervention:   Other: No intervention
Sponsor:   Pfizer
Not yet recruiting - verified September 2016

Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)

Condition:   Hypercholesterolemia
Interventions:   Drug: ALIROCUMAB SAR236553 (REGN727);   Drug: placebo (for injection training only)
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified September 2016

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3

Condition:   Hyperlipidemia
Interventions:   Drug: Part A, Atorvastatin;   Other: Part A, Placebo (administered orally);   Drug: Part B, Evolocumab;   Other: Part B, Placebo (administered orally);   Drug: Part B, Ezetimibe;   Other: Part B, Placebo (administered subcutaneously);   Drug: Part C, Evolocumab
Sponsor:   Amgen
Active, not recruiting - verified September 2016

The Alberta Vascular Risk Reduction Community Pharmacy Project: RxEACH

Conditions:   Diabetes;   Chronic Kidney Disease;   Established Atherosclerotic Vascular Disease;   Framingham Risk Score >20%
Intervention:   Other: Advanced Care
Sponsors:   University of Alberta;   Alberta Health & Wellness;   Alberta Health Services;   Merck Frosst Canada Ltd.
Completed - verified September 2016

Effect of APL180 on Endothelial Function in Familial Hypercholesterolemia Patients

Condition:   Familial Hypercholesterolemia
Interventions:   Drug: APL180;   Drug: APL180;   Drug: Placebo
Sponsor:   Novartis Pharmaceuticals
Withdrawn - verified September 2016

Model System for Transient Forearm Blood Vessel Dysfunction

Conditions:   Limb Ischemia;   Ischemic Preconditioning
Interventions:   Procedure: Limb Ischemia;   Drug: Acetylcholine
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 2009

Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia

Conditions:   Mixed Dyslipidemia;   Hypercholesterolemia
Intervention:   Drug: Fluvastatin
Sponsor:   Novartis
Completed - verified September 2016